Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No worries mate. I don't see a big move up for pps until Q4, so am biding my time now and buying other stocks to diversify a bit.
Try 'saorsa' ;) it is gaelic for freedom
Apologies, I forgot prescriptions are free in Scotland (should know this since I am scottish). England and wales it is 8.25 gbp for one.
Are the royalties based on % of sale price, or % of profit?
In uk it is a fixed prescription charge that is paid by the patient, that charge is what the NHS will have to pay for it I would think. For UK I am happy to see the higher price since it should not impact sales much, but improves profit margins.
I don't expect to see any reports regarding sales until the quarterly report for Q3 is published. I may be wrong though.
It would be nice if they gave us launch dates for Abbott and the remaining Euro partners soon.
Love it Carlo...time for another large bombay blue saphire and tonic...
Yes, very happy to see they timed the launch of the site for today. Looks great!
17.20 here in singapore so I will wait for news in a bar! :)
I would not count on Takeda making a press release considering the lack of communication so far regarding Vitaros.
Looking at their website, the news section is pretty sparse:
http://www.takeda.co.uk/about-takeda/latest-news/
January 2014
Takeda to market the Calcichew® portfolio in the United Kingdom and Ireland following transfer of Marketing Authorisation from Shire Pharmaceuticals Ireland Limited
Click to download the press release
Takeda UK supports production of DUK's State of the Nation Report 2013
Diabetes UK's 2013 State of the Nation Report shows that diabetes continues to be a major challenge for the NHS. It is still a huge drain on resources, quality of care still depends on where you live, and the crisis is still not being taken seriously. The key problems highlighted in 2012 remain and will worsen as the numbers involved increase.
Click to view the recently published Diabetes UK's 2013 State of the Nation Report
Click to view the Diabetes UK 2013 State of the Nation Infographic
November 2013
Takeda choir lights up Wooburn
The Takeda choir made its debut at the Wooburn Christmas lights switch-on in November, performing with none other than Father Christmas at the charity event. The choir, which only began rehearsing in September, sang a number of Christmas favourites to support the fundraising efforts of event organiser, the Wooburn Club. As well as Father Christmas, the choir was joined by local children in a unique rendition of Jingle Bells. All monies raised from the event went towards maintaining the villiage's Christmas lights.
If you ban him, he will appear with a new name, this way at least it is easy to recognise it is a nonsense post
As far as I am aware, Abbot is not working on room temp, they have allegedly been working just on extending the shelfife of the normal V
Not for us since they sold the US rights for peanuts
I agree Shazam, if Vitaros is a hit in Europe, it would be very poor business sense for Actavis to give up any rights. The only thing that could entice them is a big share of Femprox rights in US I think and I would prefer the company to keep that.
I would expect the pharm cos to make the first announcement rather than APRI.
Shazam, I love your positive attitude, but I do think it needs a serious reality check based on current pps performance. I have a lot of shares now and if your fantasy comes true, I will buy you a double mojito in venue of your choice. However, I think things will move a lot slower due to previous issues.
Come to Thailand mate, you will see a fair few 50somethings with young pregnant wives ;)
What is the reason for this?
Vitaros should not be used for sexual intercourse with a woman with child-bearing potential unless the couple uses a condom barrier.
Good news to see another agreement with recurring revenue
I'm sure Vissium didnt buy a million shares because they thought apri would flop
I am hoping even with no announcement prior to 16th June, we will continue the steady increase in PPS that we have seen the past few days.
Would be nice to find out some feedback from users who have tried the early samples, but I haven't managed to find anything online. Still nothing on Takeda's UK website in the products section either, so I sent an email enquiry this morning asking about Vitaros.
Spherix made a PR regarding the shelving of the patent legislation last week and stock price went up 120% in 2 days. Would be nice if Wi-Lan did the same since they are in the same line of business
I agree with your points RVL. Good uptake/feedback of Vitaros in Europe (and hopefully Canada soon) and a good partnership for Femprox and the PPS should fly, Ray-va should make little difference. If Vitaros tanks and Femprox doesn't make it to market, this will be a penny stock, again Ray-va or no Ray-va.
I guess if you have reynauds and erectile dysfunction, you can put a load of cream on your hands then choke the chicken to kill 2 birds with one stone :)
Ok, didn't know about the Monday holiday.
25k shares traded Friday...what happened, was everyone in USA on holiday?? Anyway, 3 days running in the green has made me happy for the weekend. :)
Yesterday is the first time in a month getting a positive move 2 days running...about time too!
I paid $50 for 50 x 100mg sachets of kamagra jelly in bangkok a couple of months ago...dont see a huge asian market for V with that competition
How do you know what websites other board members use as research aids?
I may buy another 10k shares when I get paid june 7th...that or vtnr anyway :)
No it shouldn't...the original is fine, not my fault you don't know how Zacks ranks companies
One of my other stocks changes 1 to 2 and 2 to 1 rank almost every 2 days
3 = hold, 4 = sell. Not an upgrade.
Roth changed their estimate on eps for 2015 a few days ago and they think apri will lose more money now. Also didnt help with the 200% eps miss for first Q. We know it was due to deferred registering of the up front payments, but maybe zacks don't.
Someone needs to tell Zacks all the good stuff about APRI...they just downgraded them from 3 to 4 today :(
http://www.dailymail.co.uk/health/article-2630411/Could-CREAM-replace-Viagra-tablets-without-nasty-effects.html
I think someone should write to the Daily Mail and let them know about Vitaros next month
Not sure why people here think there will be long transportation times. I'm sure this will be airfreight as the weight really isnt much even with packaging. Ive been sending 18" diameter 25mm thick 12m long steel oil pipes around the world by air recently, so a few 100mcg of vitaros isnt much!
Would be nice if they updated www.takeda.co.uk site with Vitaros since they will launch in 1 month. Nothing in the products or pipeline link from the page.
I think $5 by December is a bit more realistic based on how slow progress has been so far. Even that is looking on the optimistic side IMHO since the market is not being very friendly anymore towards companies with no positive cashflows. But I would love it if you are correct Shazam and I am wrong!
Just read the full transcript from Seeking Alpha. Really poor show on the Q&A session.
I am with JSB and SB (who's post disappeared) regarding Ray-Va. Strikes me as a smokescreen announcement to try to make up for missing guidance on Femprox and announcing zero revenue for the quarter.
Very strange after hours trading when I look at Nasdaq also. Will be very curious to see how it opens tonight. Just a shame I am tucked up in bed 30 mins after trading opens most days, so don't get to monitor how things are playing out! :P
Nice update Carlo, thanks for sharing